Abstract 85P
Background
Characterization of the immune microenvironment is key. In tumors with wide presence of genomic alterations like non-small cell lung cancer (NSCLC) the evaluation of the immune profile can help to better select treatment options. In this study we explored the transcriptomic landscape of lung adenocarcinoma tumors (LUAD) with genomic alterations at SMARCA4.
Methods
Data from TCGA was downloaded to evaluate the expression of transcripts up or down regulated when deletions or disruptive mutations of SMARCA4 were present in LUAD. Median values were used and genes with fold change (FC) > than 2.5 were selected. Gene set enrichment analysis was performed with Enricher. TIMER platform was employed to investigate the association with immune cell populations.
Results
Of the 507 evaluated patients, disruptive mutations were present in 43 and gene deletions in 5. Molecular/biological functions enriched within the upregulated genes in tumors with SMACA4 deletions included: ncRNA 3'-end processing (GO:0043628) or ketosteroid monooxygenase activity (GO:0047086), among others; involving representative genes like CT45A10; SAGE1; CT45A3; CT45A5; CT45A1, AKR1C1; AKR1C2, CBR1 or CBR3. In tumors with no deletion the most represented molecular/biological functions included the antigen processing and presentation of lipid antigen via MHC class Ib (GO:0048003) with relevant genes as: CD1E; CD1C; CD1B; CD1A; CX3CR1; P2RY12, among others. Presence of CD1A, CD1B, CD1C, CD1E in tumors with no SMARCA4 genomic alterations strongly associated with the presence of dendritic cells (DC) (Corr Rho 0.41, 0.48, 0.44 and 0.45, respectively) and dendritic resting cells (DRC) (Corr Rho 0.75, 0.70, 0.71 and 0.72, respectively). A direct comparison between SMARC4 deletions and DC and DRC, showed a clear negative correlation (Corr Rho -0.5, -4,3, respectively). Similar findings were observed with SMARC4 mutations (DC Corr -0.69, DRC Corr -0.91).
Conclusions
SMARCA4 deletions in LUAD tumors associated with loss of antigen presenting genes including CD1E; CD1C; CD1B; CD1A that are present in myeloid dendritic cells. We hypothesized that loss of antigen presentation functions can be present in LUAD with genomic alterations of SMARCA4.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09